Loading organizations...
§ Private Profile · Cupertino, CA, USA
Novare Surgical is a technology company.
Novare Surgical has raised $26.0M across 2 funding rounds.
Novare Surgical has raised $26.0M in total across 2 funding rounds.
Novare Surgical Systems develops, manufactures, and markets devices for minimally invasive surgery. Its core offering, the RealHand High Dexterity (HD) Instruments, are hand-held laparoscopic tools with seven degrees of freedom. These instruments utilize the EndoLink mechanism, replicating surgeon hand movements with tactile feedback for precise 360-degree articulation. It also provides the Enclose II Device for off-pump coronary artery bypass surgery.
Founded in 1999 in Cupertino, California, Novare Surgical Systems was co-founded by Dr. Thomas J. Fogarty. The company's insight addressed the need for more dextrous instrumentation to overcome minimally invasive surgery limitations. The RealHand HD Instruments, developed internally, underscore a pivotal focus on enhancing surgeon control and precision.
Novare Surgical Systems serves surgeons and medical professionals performing minimally invasive and cardiac procedures. The company advances instrumentation by enhancing tools providing greater control and precision. Its vision centers on expanding the capabilities and safety of complex interventions, benefiting practitioners and patients through innovative technology.
Novare Surgical has raised $26.0M across 2 funding rounds. Most recently, it raised $16.0M Series D in October 2006.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2006 | $16M Series D | — | Canaan Partners | Announced |
| Jun 1, 2002 | $10M Series C | — | Canaan Partners | Announced |
Novare Surgical has raised $26.0M in total across 2 funding rounds.
Novare Surgical's investors include Canaan Partners.
# Novare Surgical Systems: Medical Device Innovator in Minimally Invasive Surgery
Novare Surgical Systems is a medical device manufacturer, not a technology company in the traditional sense. Based in Cupertino, California, and founded in 1999, the company specializes in developing and manufacturing instruments for minimally invasive surgery (MIS).[1][5] Rather than building software or digital platforms, Novare creates physical surgical instruments that enable surgeons to perform complex procedures through small incisions with greater precision and control than conventional rigid tools.
Novare's core product is the RealHand High Dexterity (HD) instrument platform, a line of articulating laparoscopic instruments featuring seven degrees of freedom of movement.[1][3] These hand-held surgical tools are designed to mirror a surgeon's hand movements while providing tactile feedback—capabilities previously unavailable without robotic systems or computer-aided assistance.[2][3] The company serves surgeons performing minimally invasive procedures across multiple specialties, including gynecologic surgery (total laparoscopic hysterectomy), cardiac surgery, and other endoscopic applications.
The problem Novare solves is fundamental to MIS: traditional rigid laparoscopic instruments limit surgeon ergonomics and the ability to reach around internal body structures.[4] RealHand instruments overcome these constraints by providing full articulation in a hand-held format, enabling surgeons to perform complex maneuvers safely and efficiently without the cost, setup time, or learning curve associated with robotic surgical systems.[2]
Novare operates at the intersection of two significant healthcare trends: the shift toward minimally invasive surgical techniques and the demand for surgeon-friendly alternatives to robotic systems. MIS procedures reduce patient trauma, scarring, and recovery time—benefits that drive adoption across healthcare systems seeking to improve patient outcomes while managing costs.[4] However, the complexity of MIS procedures has historically required either expensive robotic platforms or acceptance of the limitations of rigid instruments.
Novare's RealHand technology addresses a genuine market gap by enabling what the company calls "hidden scar surgery"—complex procedures performed through minimal incisions without robotic infrastructure.[3] This positioning matters as healthcare systems balance innovation with budget constraints, and as surgeons seek tools that enhance their natural capabilities rather than replacing their judgment with automation.
Novare Surgical Systems represents a niche but strategically important player in surgical instrumentation. The company's success hinges on clinical adoption across surgical specialties and the ability to expand its instrument portfolio beyond initial applications. As minimally invasive techniques become standard of care for an expanding range of procedures, demand for high-dexterity instruments should grow—particularly in cost-conscious healthcare environments where RealHand's advantages over robotic systems become more compelling.
The broader question for Novare is whether articulating hand-held instruments can capture meaningful market share against entrenched robotic competitors, or whether they will remain a specialized alternative for specific surgical applications and surgeon preferences. The company's trajectory will depend on clinical evidence, surgeon adoption rates, and its ability to expand into new surgical domains where the RealHand platform provides distinct advantages.